CLRB
Cellectar Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.14
+0.00%Oct 15, 2026, 11:00 UTC
Cellectar Biosciences, Inc. presented Phase 2b CLOVER WaM subgroup efficacy data for iopofosine I 131 in patients previously treated with a BTK inhibitor, reporting an 87.5% overall response rate, 79.2% major response rate, 100% clinical benefit rate and median duration of response of 16 months.
Source:Sep 29, 2026, 11:30 UTC
Cellectar Biosciences announced it will present efficacy data from a Phase 2 CLOVER subset analysis of Iopofosine I 131 in BTK inhibitor-refractory Waldenström macroglobulinemia patients at the International Workshop for Waldenström Macroglobulinemia.
Source:Aug 13, 2026, 18:57 UTC
Cellectar Biosciences, Inc. held its Q2 2026 earnings call on August 13, 2026.
Source:Aug 13, 2026, 00:00 UTC
Cellectar Biosciences announced a securities offering with aggregate upfront proceeds of approximately $35 million and potential milestone-based proceeds of up to $105 million.
Jul 15, 2026, 11:30 UTC
Cellectar Biosciences announces the publication of a Phase 1 study of Iopofosine I 131 in the peer-reviewed journal Cancers.
Source: